The Committee's Dissatisfaction With the Outcome of Yesterday's Vote

GSK argued that there's two years of protection from one shot and we feel that, you know, that added value needs to be reflected in the cost of the shot. Committee members were not satisfied with the amount of data they had from the companies,. And particularly in the populations that are most affected in the elderly by RSV and severe disease from it.